ArriVent BioPharma's lung cancer treatment did not achieve its primary goal in a Phase 3 trial.

Observed price moves

• AVBP-3.25%10 min after this headline

MoveSurge carries market-moving headlines the moment they reach the wire, each one with what the price did next.